NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy, Ste 206, Reno, NV 89521

(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444

• Web Page: bop.nv.gov

MINUTES

March 23, 2020

BOARD MEETING

Teleconference Line 1-669-900-6833 Meeting ID: 113 761 560

Board Members Present:

Krystal Freitas Jade Jacobo Wayne Mitchell Helen Park

Gener Tejero Richard Tomasso Rolf Zakariassen

Board Staff Present:

Dave Wuest Yenh Long Brett Kandt Kristopher Mangosing

1. Call to Order and Roll Call - Establishment of Quorum

President Park performed the roll call. All Board Members were present and a quorum was established.

Public Comment March 23, 2020, 2019 3:30 PM

There was no public comment.

3. Discussion and Possible Action on Adoption of Emergency Regulation pursuant to NRS 233B.0613 to Restrict the Prescribing and Dispensing of Chloroquine or Hydroxychloroquine in Response to COVID-19.

President Park opened the discussion regarding the possible adoptions of emergency regulation pursuant to NRS 233B.0613.

Mr. Wuest and Mr. Kandt provided background information regarding the emergency regulation process and proposed language.

Beth Slamowitz described the Governor's COVID-19 Medical Advisory Team's (MAT) concerns regarding the supply of chloroquine and hydroxychloroquine for use in an inpatient

setting. Ms. Slamowitz summarized the MAT's recommendations for the proposed emergency regulation.

The Board discussed the hoarding and stockpiling of chloroquine and hydroxychloroquine during the COVID-19 pandemic and the resulting shortage of supplies of these drugs for legitimate medical purposes. The Board noted that the FDA has not made any determination on the safety and efficacy of chloroquine or hydroxychloroquine for treating COVID-19.

The Board discussed an emergency regulation in NAC Chapter 639 to restrict the prescribing and dispensing of chloroquine and hydroxychloroquine for the next six months. These restrictions include prohibiting the prescribing and dispensing of chloroquine and hydroxychloroquine for a COVID-19 diagnosis or any new diagnosis made after the effective date of the regulation, and requiring an ICD-10 code and a limit to a 30-day supply for any new prescription for these drugs. The provisions of this emergency regulation would not apply to a chart order for an inpatient in an institutional setting or to an existing course of treatment for a diagnosis made before the effective date of the regulation.

Mr. Kandt read the proposed language into the recording including modifications indicated by the Board during discussion.

President Park opened the Public Comment.

There was no public comment.

Board Action:

Motion: Wayne Mitchell moved to adopt the emergency regulation, pursuant to NRS

233B.0613 as presented by Board Staff.

Second: Krystal Freitas

Action: Passed unanimously

4. Public Comment March 23, 2020 4:30 PM

Diane Rhee expressed support of the Emergency Regulation adopted by the Board.

30. Adjournment

President Park adjourned the meeting.